
Spectral Med reported positive quarterly EPS, beating expectations for a loss. Its FDA review and financing remain key parts of the investment story.
Spectral Med Inc. (TSX: EDT) reported earnings before the market opened on November 6, 2026, for the quarter ended September 30. EPS was C$0.02, compared with an estimate of -C$0.01. The company reported a 300.0% surprise. One analyst’s revenue estimate was C$604,000, but no actual revenue figure was provided, so it’s not possible to tell whether revenue beat or missed expectations. For Canadian investors, the result is one data point for a company still awaiting FDA review and relying on financing to support its operations.
Recent earnings trend
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
Market cap
$293.55M
52W high
$1.52
52W low
$0.86
1W change
-5.56%
Beta
0.19
Analyst Price Targets
Based on analyst covering EDT · as of Sep 17, 2026
Wall Street analysts forecast EDT stock price to rise 208.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+208.8% Upside
Current Price
C$1.02
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
75.9%
Annualized
90-Day Vol
52.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.85
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.96 | C$0.74 – C$1.25 |
| 60 trading days | C$0.91 | C$0.63 – C$1.31 |
| 90 trading days | C$0.85 | C$0.54 – C$1.34 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 3 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-29 | — | -0.0100 | — |
| 2026-09-30 | 2026-11-06 | 0.0200 | -0.0100 | +300.0% |
| 2026-06-30 | 2026-08-07 | 0.0011 | -0.0100 | +111.0% |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
Investor takeaway: EPS came in above expectations, and Spectral has beaten estimates in three of its last four reported quarters. Still, the figures are small: trailing-twelve-month (TTM) EPS is -C$0.03, and the reported profit margin is 0.00%. The company says recent financing should fund operations through the expected FDA PMA decision. The timing and outcome of the review remain uncertain. See the EDT stock page for company and share information.
C$0.02 EPS versus -C$0.01 estimated
EPS was 300.0% above the calendar estimate, but that estimate was a loss. The result doesn’t show that the company has reached lasting profitability. EPS was -C$0.11 in the same quarter last year, and TTM EPS remains -C$0.03.
Bull case
EPS improved to C$0.02 from -C$0.11 a year earlier, beating the -C$0.01 estimate. In a September update, Spectral said the FDA had requested clarification, further data analysis and testing, but no additional clinical trial. The company is preparing a response and says recent financing should cover operations through the expected PMA decision. Addressing the FDA’s feedback and moving the review forward would be an important milestone.
Bear case
One quarter of positive EPS doesn’t establish lasting profitability. TTM EPS is still negative, and the reported margin is 0.00%. The revenue estimate implied a 10.5% year-over-year decline, but actual revenue wasn’t included in the earnings data. The FDA review still requires a response, and its timing and outcome are uncertain.
Financing is another consideration. Spectral announced the second tranche of a C$14 million convertible-note private placement. The funds support operations, but the financing also carries potential dilution. The shares closed at C$1.02, below their 50-day average of C$1.11 and 200-day average of C$1.30.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.


